



SHIRATORI

COMPANY PROFILE



SHIRATORI Pharmaceutical Co., Ltd.

Shiratori Pharmaceutical Co., Ltd.

supports healthy lifestyles through collaboration and strong alliances with our partners.

Our goal is to become a pharmaceutical company that "change the world."

The dedication of our predecessors has brought brilliant achievements and success for our company and our homeland, Japan. As a society, we are evolving through continuous change and are faced with and concerned about stagnant growth. Shiratori Pharmaceutical's experience in navigating its business, like Japan's period of economic growth and advancement, may paradoxically mask our ability to continue to perform at such a high level. It could be a factor which influences our future performance and presents difficulties for our business.


As we turn the page to a new era at Shiratori Pharmaceutical Co., Ltd., we pursue both change and continuity so we can become a company which promotes healthy lifestyles through collaboration and strong alliances with our partners. While maintaining our competent advantage, Shiratori Pharmaceutical aims to create new perspectives and innovative visions.

We are confident that our progressive and ambitious company culture will attract and satisfy our partners, our employees, and everyone else in this industry.



Satoshi Shiratori

Representative Director
and President





SHIRATORI

Shiratori Pharmaceutical is a flexible company bursting with creative strengths.

With natural ingredients as our starting point,
we have dedicated many years to the development
of active pharmaceutical ingredients (APIs) and intermediates,
functional organic compounds, and beauty and health food products.

Our entire workforce constantly strives to be innovative, flexible and creative.
As a company that has grown based on a research and development model,
we at Shiratori Pharmaceutical believe that our mission is to enhance the quality of life (QOL)
of our customers through the development, manufacturing,
and sales of APIs and health foods.



contents

Message from the President
Shiratori's Challenges
Shiratori's Goals 1
Shiratori's Goals 2
Shiratori's Goals 3
Shiratori's Functions 1
Shiratori's Functions 2
Shiratori's Functions 3
Shiratori's Functions 4
Company Profile

We produce APIs and intermediates that protect human health.

We use the latest technologies and equipment under strict standards of quality control in accordance with GMP (Good Manufacturing Practice) and the FDA (Food and Drug Administration of the United States) regulations to produce APIs and intermediates, which are vital for protecting human life.

The APIs and intermediates that we bring forth are primarily used for anticancer drugs, cardiovascular drugs, antiallergic drugs, and other pharmaceutical products that are essential for human beings.

We believe that reliable quality is the most important factor in manufacturing APIs. By combining human resources, an organizational system, and other intangible elements with suitable equipment units and systems, a control environment, and other tangible elements, we leverage a foundation built on proprietary technologies. These include methods for producing compounds through natural plant extractions and the latest catalysts. As a result, we have continuously provided APIs that meet the high standards of Japanese authorities and the FDA, while also satisfying the needs of many domestic and international pharmaceutical companies.

We will continue to produce high-quality APIs tied to human health in a manner that is consistent with the reputation for reliability that we have built to established.

CONTRIBUTION

We cultivate organic compounds imbued with unlimited functional possibilities.

We also harness the technologies and reliability we have accrued through the production of APIs and intermediates to actively engage in the field of IT as well as in original activities in the field of organic chemistry, such as developing organic compounds and catalysts that are designed to induce novel reactions.

Technologies for synthesizing chemical compounds and producing high-purity APIs, various equipment systems such as facilities for cryogenic reactions and photoreactions, and a quality assurance system developed through our pharmaceutical operations are applied to provide chiral compounds as well as functional compounds used in the field of IT.

INFINITY

We develop next-generation health foods in pursuit of human health and beauty.

At Shiratori Pharmaceutical, we also harness the technologies and reliability we have accrued through the development of APIs to focus on the contract manufacturing of health food products designed to promote human health and beauty and the development of natural ingredients and products that constitute the raw ingredients for beauty foods, health drinks, cosmetics made using natural ingredients and more.

Given the aging of society and an increase in the rate of lifestyle-related diseases in recent years, there is now a greater emphasis on prevention and awareness of the importance of health foods. Utilizing technologies and know-how cultivated over a century of experience in developing APIs, the Shiratori Pharmaceutical Group is focusing on the development of natural materials with proven efficacy and safety, as well as the contract manufacturing of health food products.

In addition, we offer our clients products that have been traditionally consumed, with their efficacy and safety verified through joint research conducted with domestic national and international universities.



Research and development functions

Our R&D Center is responsible for the development of APIs, pharmaceutical intermediates, functional organic compounds, and health foods through the constant incorporation of the latest synthesis and analytical technologies. Furthermore, this division takes on the important role of facilitating technology transfers to our manufacturing, quality assurance, and quality control divisions in order to smoothly implement newly developed methods and techniques on a plant-wide scale.

Research and Development Activities

- Developing and improving of processes
- Optimizing and increasing the scale of processes
- Developing analytical methods and applying them to quality control
- Developing new synthesis technologies and acquiring rights



We prioritize nurturing researchers with a challenging spirit, enabling them to adapt to the times and drive change. Our researchers deeply understand the R&D Center's vision of "Creating Products to Save the World," which allows them to make accurate decisions even in difficult situations through swift execution and adjustment.

We aim not to predict the future but to create it. By analyzing reality, thinking thoroughly, and taking on challenges without being bound by past successes, we create the true future. We believe it is essential to constantly think about the future, act proactively, and turn imagination into reality. Our researchers contribute to the realization of innovative products by striving towards their dreams and goals and enhancing their creativity.

In chemical experiments, focusing on key points is crucial. Our experiments aim to develop methods rather than just finding them. Our foundational experiments are guided by three principles: grasping facts, elucidating truths, and conducting research with integrity. We always strive to create new starting points, look towards the future, act proactively, and turn imagination into reality.



Production system and quality control for High Potency Active Pharmaceutical Ingredients (HPAPIs)

Amid intensifying competition for generic drugs, we at Shiratori Pharmaceutical anticipate an increase in demand for HPAPIs that exert strong effects in small amounts, such as anticancer drugs, due to the aging population. To differentiate ourselves from other pharmaceutical factories, we operate the Akanehama Research Institute, a factory specializing in the manufacturing of HPAPIs, which are difficult to handle and scale, and therefore have high added value.

This factory adheres to the strict requirements of GMP, is equipped with "containment equipment" that isolates the work space from the surrounding environment to prevent the dispersion and cross-contamination of highly active substances, and is capable of performing exposure management to reduce worker exposure levels.



Quality control is an important task that involves testing whether HPAPIs meet strict quality standards to ensure the efficacy of pharmaceuticals and patient safety. When testing HPAPIs, it is necessary to minimize risks to workers and the environment; therefore, at the Akanehama Research Institute, our testing laboratories are equipped with containment equipment that can handle the testing of HPAPIs, and quality control is conducted with comprehensive consideration from multiple angles, such as environmental and worker protection.

Manufacturing system

We manufacture high-quality products by harnessing our proprietary technologies and cutting-edge equipment.

At Shiratori Pharmaceutical, we have made full use of synthesis methods, based primarily on chemical reactions, and purification methods to manufacture APIs, intermediates, experimental drugs, functional organic compounds, and more. We have forged a solid position for ourselves in the APIs industry by leveraging our exceptional technologies.

A GMP system that meets domestic, European, American, and other foreign requirements

We manufacture products at an appropriate level of quality in conformity with the requirements of domestic, European, American, and other foreign regulatory authorities, as well as the needs of our clients. Our Chiba Plant underwent an inspection conducted by the FDA, which recognized that a framework of cGMP is appropriately in place.



An environmentally friendly manufacturing system

Our Chiba Plant has obtained ISO 14001 certification and is continuously engaged in efforts to reduce its environmental load.

Manufacturing systems to meet various client needs



Quality assurance system

To ensure that our customers can use our high-quality products with confidence, we have established and currently manage an advanced quality assurance system and strive to maintain and improve this system in accordance with our prescribed quality policies. This is because we believe that high-quality products that are provided through a superior quality assurance system can help promote human health and earn the unwavering trust of our clients.

Quality policies

We have established 'Quality Policy' and are committed to achieving it in order to contribute to the improvement of our customers' quality of life.

- Appropriately operate the pharmaceutical quality system and maintain high quality and reliability through continuous improvement.
- Comply with relevant laws and regulations, understand customer needs, and provide products that satisfy customers.
- Raise awareness of quality through continuous education and enlightenment, and foster quality culture.




Company Profile


■ Company Name	Shiratori Pharmaceutical Co., Ltd.
■ Head Office	WBG Marive East 28F, 2-6-1 Nakase, Mihama-ku, Chiba-shi, Chiba Tel: +81(43)307-8977 Fax: +81(43)299-8970
■ Representative Director & President	Satoshi Shiratori
■ Established	1948 Originally founded in 1916
■ Capital	95,000,000 yen
■ Annual Turnover	6.7 billion yen (As of August 31, 2025)
■ Business Details	Manufacturing of APIs Manufacturing of fine chemicals Manufacturing of health foods Contract research/manufacturing of APIs and intermediates
■ Number of Employees	210 (As of June 1, 2026)
■ Main Banks	Chiba Bank (Tsudanuma branch) Shoko Chukin Bank (Chiba branch) Sumitomo Mitsui Bank (Funabashi Corporate Business Office) Chiba Kogyo Bank (Tsudanuma branch) Mizuho Bank (Chiba branch) Mitsubishi UFJ Bank (Funabashi branch) Keiyo Bank (Tsudanuma branch)
■ Chiba Plant	54 Shinminato, Mihama-ku, Chiba-shi, Chiba Tel: +81(43)242-7631 Fax: +81(43)246-7473
■ Shinminato Office	14-5 Shinminato, Mihama-ku, Chiba-shi, Chiba
■ Tokyo Office	5F +SHIFT Nihonbashi Sakura-dori, 3-14-3 Nihonbashi, Chuo-ku, Tokyo Fax: +81(3)3258-6072
■ Research and Development Center	6-11-24 Tsudanuma, Narashino-shi, Chiba Tel: +81(47)452-3192 Fax: +81(47)452-3193
■ Akanehama Research Institute	2-3-7 Akanehama, Narashino-shi, Chiba Tel: +81(47)453-3168 Fax: +81(47)452-3158
■ Affiliates	● Shiratori Yakuhin Co., Ltd. Sales of APIs and fine chemicals Import and sales of APIs, chemical products, and raw materials for food products Sales of health foods ● Seiko Yakuhin Kogyo Co., Ltd. Contract manufacturing, planning, and development of health food products and manufacturing and sales of health food ingredients ● Shiratori Wellpharma Co., Ltd. Mail-Order sales of health food products

Corporate History


1916	Founder Yosouzaemon Shiratori achieves domestic production of caffeine and establishes Shiratori Seiyakusho.
1948	The company is incorporated as Shiratori Pharmaceutical Co., Ltd., and Yosouzaemon Shiratori assumes the role as the first president.
1950	Shiratori Yakuhin Co., Ltd., is established as a sales company.
1969	The Chiba Plant is opened in the Chiba Mihama-ku Shinminato Shokuhin Industrial Complex. The Tokyo branch office is opened to reinforce sales.
1971	The Chiba Plant is enlarged.
1977	A research laboratory is set up on the premises of the head office (currently the R&D Center).
1988	Capital participation by the Tokyo Small and Medium Business Investment Consultation Company is secured. Capital is increased to 95 million yen.
1996	A pre-approval inspection is conducted by the FDA; it is recognized that a framework of current good manufacturing practices (cGMP) is in place. The Sales Division and head office operations are transferred to the newly constructed Akanehama head office in Narashino-shi, Chiba.
1998	Yutaka Shiratori is appointed president.
2002	The company is granted a regional award by the Medium and Small Business Research Institute (presently known as the Good Company Award for corporate excellence).
2003	The Chiba Plant obtains ISO 14001 certification.
2007	New API facilities are added on the premises of the Chiba Plant.
2010	A foreign pre-approval and GMP surveillance inspection for a site change is conducted by the FDA; it is recognized that the firm is following ICH Q7 guideline without observation/FDA-483.
2013	The Chiba Plant obtains FSCC22000 certification. The Akanehama Research Institute opens to produce highly potent APIs.
2016	The company celebrates its 100th anniversary. The Shinminato Office (QC center) opens in Shinminato, Mihama-ku, Chiba-shi.
2017	The Tokyo Office is opened in Kanda (Chiyoda-ku, Tokyo), and the Sales & Development Division and Wellpharma Division are transferred. Yutaka Shiratori is appointed chairman, and Satoshi Shiratori is appointed president.
2019	The head office is relocated to Makuhari New City.
2020	A new research building opened at the R&D Center.
2023	At the Spring Conferment of Decorations, Yutaka Shiratori received the Order of the Rising Sun, Gold Rays with Rosette.
2023	The Akanehama Research Institute is rebuilt to produce highly potent APIs.
2025	Sephapterin (Sephience™), manufactured using a process developed by Shiratori Pharmaceutical, is approved as a treatment for phenylketonuria (PKU) in Europe, the United States, and Japan.
2026	The company celebrates its 110th anniversary. The Tokyo Office is relocated to Nihonbashi.




[Head Office]
WBG Marive East 28F,
2-6-1 Nakase, Mihama-ku, Chiba-shi, Chiba



[Research and Development Center]
6-11-24 Tsudanuma, Narashino-shi, Chiba
[Akanehama Research Institute]
2-3-7 Akanehama, Narashino-shi, Chiba



[Chiba Plant]
54 Shinminato, Mihama-ku,
Chiba-shi, Chiba
[Shinminato Office]
14-5 Shinminato, Mihama-ku,
Chiba-shi, Chiba



[Tokyo Office]
5F +SHIFT Nihonbashi Sakura-dori,
3-14-3 Nihonbashi, Chuo-ku, Tokyo